What evidence exists to support the use of intensive lipid-lowering therapy to reduce coronary heart disease risk?
Evidence exists to support the use of intensive lipid-lowering therapy to reduce coronary heart disease risk. This is evidenced by a number of studies, such as the Treating to New Targets (TNT) study, the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) study, the Cholesterol Treatment Trialists (CTT) Collaborators meta-analysis, the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) report, and the Robinson et al. meta-analysis. Additionally, the Zhao et al. study found that intensive lipid-lowering therapy had positive effects on the coronary arteries of asymptomatic subjects with elevated apolipoprotein B. Overall, these studies provide evidence to support the use of intensive lipid-lowering therapy to reduce coronary heart disease risk.  